Is Silence Therapeutics Stock a Good Investment?
Silence Therapeutics Investment Advice | SLN |
- Examine Silence Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Silence Therapeutics' leadership team and their track record. Good management can help Silence Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Silence Therapeutics' business and its evolving consumer preferences.
- Compare Silence Therapeutics' performance and market position to its competitors. Analyze how Silence Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Silence Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Silence Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Silence Therapeutics PLC stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Silence Therapeutics PLC is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Silence Therapeutics Stock
Researching Silence Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company outstanding shares are owned by corporate insiders. The book value of Silence Therapeutics was at this time reported as 0.43. The company recorded a loss per share of 1.69. Silence Therapeutics PLC had not issued any dividends in recent years.
To determine if Silence Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Silence Therapeutics' research are outlined below:
| Silence Therapeutics generated a negative expected return over the last 90 days | |
| Silence Therapeutics has high historical volatility and very poor performance | |
| Silence Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 25.38 M. Reported Net Loss for the year was (50.31 M) with profit before taxes, overhead, and interest of 6.62 M. | |
| Silence Therapeutics PLC has about 51.56 M in cash with (39.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72. | |
| Roughly 63.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels |
Silence Therapeutics Quarterly Accounts Payable |
|
Silence Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Silence Therapeutics PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Silence Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Silence Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Silence Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-16 | 2023-03-31 | -0.1504 | -0.1184 | 0.032 | 21 | ||
2022-09-14 | 2022-06-30 | -0.1961 | -0.1518 | 0.0443 | 22 | ||
2023-08-16 | 2023-06-30 | -0.1729 | -0.1224 | 0.0505 | 29 | ||
2024-05-14 | 2024-03-31 | -0.1144 | -0.0541 | 0.0603 | 52 | ||
2022-05-16 | 2022-03-31 | -0.1908 | -0.1054 | 0.0854 | 44 | ||
2023-11-14 | 2023-09-30 | -0.17 | -0.07 | 0.1 | 58 | ||
2022-11-10 | 2022-09-30 | -0.2011 | -0.0841 | 0.117 | 58 | ||
2024-08-15 | 2024-06-30 | -0.1145 | -0.4277 | -0.3132 | 273 |
Know Silence Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Silence Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Silence Therapeutics PLC backward and forwards among themselves. Silence Therapeutics' institutional investor refers to the entity that pools money to purchase Silence Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Eventide Asset Management, Llc | 2024-09-30 | 640 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 608 K | Adage Capital Partners Gp Llc | 2024-06-30 | 600 K | Ikarian Capital, Llc | 2024-09-30 | 587.3 K | Saturn V Capital Management Llc | 2024-09-30 | 481.1 K | 5am Venture Management, Llc | 2024-09-30 | 476.2 K | Point72 Asset Management, L.p. | 2024-09-30 | 467.8 K | Citadel Advisors Llc | 2024-09-30 | 436.7 K | Cormorant Asset Management, Llc | 2024-09-30 | 400 K | Tcg Crossover Management, Llc | 2024-09-30 | 3 M | Logos Global Management Lp | 2024-06-30 | 3 M |
Silence Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 779.04 M.Market Cap |
|
Silence Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.65) | (0.68) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (2.54) | (2.41) |
Determining Silence Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Silence Therapeutics is a good buy. For example, gross profit margin measures Silence Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Silence Therapeutics' profitability and make more informed investment decisions.
Evaluate Silence Therapeutics' management efficiency
Silence Therapeutics PLC has Return on Asset of (0.2154) % which means that on every $100 spent on assets, it lost $0.2154. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6428) %, meaning that it generated no profit with money invested by stockholders. Silence Therapeutics' management efficiency ratios could be used to measure how well Silence Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.68. At this time, Silence Therapeutics' Fixed Asset Turnover is very stable compared to the past year. As of the 26th of November 2024, Asset Turnover is likely to grow to 0.28, while Non Current Assets Total are likely to drop about 8.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.46 | 0.44 | |
| Tangible Book Value Per Share | 0.24 | 0.23 | |
| Enterprise Value Over EBITDA | (9.10) | (9.55) | |
| Price Book Value Ratio | 29.71 | 31.20 | |
| Enterprise Value Multiple | (9.10) | (9.55) | |
| Price Fair Value | 29.71 | 31.20 | |
| Enterprise Value | 452.9 M | 475.5 M |
The decision-making processes within Silence Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 1.29 |
Basic technical analysis of Silence Stock
As of the 26th of November, Silence Therapeutics has the Coefficient Of Variation of (598.42), variance of 35.18, and Risk Adjusted Performance of (0.12). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Silence Therapeutics PLC, as well as the relationship between them.Silence Therapeutics' Outstanding Corporate Bonds
Silence Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Silence Therapeutics PLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Silence bonds can be classified according to their maturity, which is the date when Silence Therapeutics PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Silence Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Silence Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.67) | |||
| Mean Deviation | 3.07 | |||
| Coefficient Of Variation | (598.42) | |||
| Standard Deviation | 5.93 | |||
| Variance | 35.18 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (1.18) | |||
| Total Risk Alpha | (1.94) | |||
| Treynor Ratio | (0.68) | |||
| Maximum Drawdown | 49.65 | |||
| Value At Risk | (8.72) | |||
| Potential Upside | 4.7 | |||
| Skewness | (3.36) | |||
| Kurtosis | 20.49 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.67) | |||
| Mean Deviation | 3.07 | |||
| Coefficient Of Variation | (598.42) | |||
| Standard Deviation | 5.93 | |||
| Variance | 35.18 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (1.18) | |||
| Total Risk Alpha | (1.94) | |||
| Treynor Ratio | (0.68) | |||
| Maximum Drawdown | 49.65 | |||
| Value At Risk | (8.72) | |||
| Potential Upside | 4.7 | |||
| Skewness | (3.36) | |||
| Kurtosis | 20.49 |
Consider Silence Therapeutics' intraday indicators
Silence Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Silence Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Silence Therapeutics Corporate Filings
6K | 18th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 22nd of October 2024 Other Reports | ViewVerify | |
| 14th of May 2024 Other Reports | ViewVerify |
Silence Stock media impact
Far too much social signal, news, headlines, and media speculation about Silence Therapeutics that are available to investors today. That information is available publicly through Silence media outlets and privately through word of mouth or via Silence internal channels. However, regardless of the origin, that massive amount of Silence data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Silence Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Silence Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Silence Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Silence Therapeutics alpha.
Silence Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Silence Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Silence Therapeutics Corporate Management
| John Strafford | Alliance Devel | Profile | |
| Rhonda Hellums | Chief Officer | Profile | |
| Eric Floyd | VP Assurance | Profile | |
| Gem Hopkins | Head Communications | Profile | |
| Gianine Esposito | Chief Officer | Profile | |
| Giles MD | Head VP | Profile | |
| Jrgen Wittendorff | VP Manufacturing | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.69) | Revenue Per Share 0.429 | Quarterly Revenue Growth (0.93) | Return On Assets (0.22) | Return On Equity (0.64) |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Silence Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.